Please assess the completion status of the following clinical trial:

Trial Title: Naltrexone for Individuals of East Asian Descent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* current (i.e., past month) alcohol dependence~* East Asian ethnicity (i.e., Chinese, Korean, or Japanese)~* Prospective genotyping for the A118G SNP of the mu opioid receptor (OPRM1) gene to allow for balanced groups on all three genotypes (AA, AG, GG)~Exclusion Criteria:~* lifetime DSM-IV of drug dependence (other than alcohol or nicotine)~* current use of psychoactive drugs as determined by self-reports and verified using toxicology testing~* lifetime diagnosis of bipolar disorder or any psychotic disorder~* contraindications to an MRI scan (including left handedness)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone (Type: EXPERIMENTAL): Naltrexone 50 mg/day
- Sugar pill (Type: PLACEBO_COMPARATOR): Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).